Teva Pharmaceutical Industries Ltd (TEVA) Q3 2024 Earnings Call Highlights: Strong Revenue ...

Teva can benefit from US-made generics push and expects positive safety label for olanzapine LAI. Strong 2025 outlook for US generics and UZEDY patients from oral medications. TAPI divestment on track, no immediate cash impact from European fine.